Product Information
FEBUXOSTAT 40 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1911 per EA under NDC 00904739546. Its NADAC has been published 141 times since Jan 24, 2024.
FDA first approved this application on Dec 30, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Febuxostat market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904739546
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FEBUXOSTATApproval Type
Generic (ANDA)
FDA Application
ANDA210461FDA Approved
12/30/2019
TE Code
AB
On Market Since
12/30/2019
Pharmacological Classes
Price Statistics
The NADAC for FEBUXOSTAT 40 MG TABLET has been published 141 times since Jan 24, 2024, and over the history we have for it it has declined 52.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1911 per EA |
|---|---|
| All-time high | $0.5086 (Apr 10, 2024) |
| All-time low | $0.1911 (Sep 23, 2026) |
| 52-week high | $0.2464 |
| 52-week low | $0.1911 |
| Median price | $0.3267 |
| Average price | $0.3089 |
| Largest weekly change | -29.6% (Apr 17, 2024) |
| Weeks tracked | 141 |
| Tracking since | Jan 24, 2024 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Febuxostat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FEBUXOSTAT 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FEBUXOSTAT 40 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1911 per EA (NDC 00904739546), effective Sep 30, 2026.
How has the price of FEBUXOSTAT 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for FEBUXOSTAT 40 MG TABLET has declined 52.7%. It has been tracked across 141 weekly CMS publications since Jan 24, 2024.
What are the highest and lowest recorded NADAC prices for FEBUXOSTAT 40 MG TABLET?
Since Jan 24, 2024, the NADAC for FEBUXOSTAT 40 MG TABLET has ranged from a low of $0.1911 (Sep 23, 2026) to a high of $0.5086 (Apr 10, 2024), with a median of $0.3267 per EA.
Are there cheaper alternatives to FEBUXOSTAT 40 MG TABLET?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FEBUXOSTAT 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FEBUXOSTAT 40 MG TABLET?
FEBUXOSTAT 40 MG TABLET (NDC 00904739546) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.